Precigen logo

PrecigenNASDAQ: PGEN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 August 2013

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$245.82 M
-78%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-48%vs. 3y high
85%vs. sector
-48%vs. 3y high
91%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:39:46 GMT
$0.84+$0.02(+1.89%)

Dividend

No data over the past 3 years
$717.00 K$1.25 M
$717.00 K-$58.79 M

Analysts recommendations

Institutional Ownership

PGEN Latest News

Precigen to Participate in the 2024 Cantor Global Healthcare Conference
prnewswire.com16 September 2024 Sentiment: POSITIVE

GERMANTOWN, Md. , Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Wednesday, September 18, 2024 from 9:45 to 10:15 AM ET at the 2024 Cantor Global Healthcare Conference taking place September 17 to 19, 2024 in New York.

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript
seekingalpha.com14 August 2024 Sentiment: NEUTRAL

Precigen, Inc. (NASDAQ:PGEN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Steven Harasym - VP, IR Helen Sabzevari - President & CEO Harry Thomasian - CFO Phil Tennant - Chief Commercial Officer Rutul Shah - COO Conference Call Participants Carolina Ibanez Ventoso - Stifel Jason Butler - Citizens JMP Swayampakula Ramakanth - H.C. Wainwright Jennifer Kim - Cantor Fitzgerald Operator Good evening and welcome to the Precigen's Second Quarter and First Half 2024 Financial Results Call.

Precigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates
zacks.com14 August 2024 Sentiment: NEGATIVE

Precigen, Inc. (PGEN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
prnewswire.com14 August 2024 Sentiment: POSITIVE

– In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of RRP patients achieved Complete Response – – In July 2024, the Company appointed Phil Tennant as Chief Commercial Officer to spearhead potential PRGN-2012 commercial launch – – In August 2024, the Company announced a strategic reprioritization of its pipeline to focus on advancement of its lead program, PRGN-2012 in RRP – – PRGN-2012 rolling BLA submission, under an accelerated approval pathway, is anticipated in the second half of 2024; the Company has initiated enrollment in the confirmatory clinical trial of PRGN-2012 – – In August 2024, the Company strengthened its cash position by raising approximately $31.4 million via a public offering of common stoc k – GERMANTOWN, Md. , Aug. 14, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2024 financial results and business updates.

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
prnewswire.com09 August 2024 Sentiment: POSITIVE

GERMANTOWN, Md. , Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024.

Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
zacks.com07 August 2024 Sentiment: NEGATIVE

Precigen (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
prnewswire.com23 July 2024 Sentiment: POSITIVE

–  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis  – GERMANTOWN, Md. , July 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer.

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
prnewswire.com23 May 2024 Sentiment: POSITIVE

GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research14 May 2024 Sentiment: NEGATIVE

Precigen, Inc. (PGEN) reported a quarterly loss of $0.10 per share, slightly missing the Zacks Consensus Estimate of a loss of $0.09. This is the same as the loss of $0.10 per share reported in the same quarter last year.

Precigen: RRP Targeting With AdenoVerse Technology Platform
Seeking Alpha19 January 2024 Sentiment: POSITIVE

FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis.

What type of business is Precigen?

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

What sector is Precigen in?

Precigen is in the Healthcare sector

What industry is Precigen in?

Precigen is in the Biotechnology industry

What country is Precigen from?

Precigen is headquartered in United States

When did Precigen go public?

Precigen initial public offering (IPO) was on 08 August 2013

What is Precigen website?

https://precigen.com

Is Precigen in the S&P 500?

No, Precigen is not included in the S&P 500 index

Is Precigen in the NASDAQ 100?

No, Precigen is not included in the NASDAQ 100 index

Is Precigen in the Dow Jones?

No, Precigen is not included in the Dow Jones index

When was Precigen the previous earnings report?

No data

When does Precigen earnings report?

The next expected earnings date for Precigen is 08 November 2024